{"id":"NCT03818035","sponsor":"Janssen-Cilag International NV","briefTitle":"A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis","officialTitle":"A Phase 3b, Randomized, Double-blind, Parallel Group, Multicenter Study to Evaluate Further Therapeutic Strategies With Guselkumab in Patients With Moderate-to-Severe Plaque-Type Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-02-08","primaryCompletion":"2022-03-07","completion":"2025-01-07","firstPosted":"2019-01-28","resultsPosted":"2023-05-10","lastUpdate":"2025-04-27"},"enrollment":880,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"Guselkumab","otherNames":["TREMFYA"]},{"type":"DRUG","name":"Placebo Injection","otherNames":[]}],"arms":[{"label":"Part 1: Guselkumab","type":"EXPERIMENTAL"},{"label":"Part 2: Guselkumab q8w and Guselkumab q16w","type":"EXPERIMENTAL"},{"label":"Part 2: Guselkumab q8w","type":"EXPERIMENTAL"},{"label":"Part 3: Guselkumab Withdrawal","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to demonstrate that Super-Responders (SRe; defined as psoriasis participants who receive on-label guselkumab treatment until week 20 and respond with a Psoriasis Area and Severity Index score (PASI) = 0 at weeks 20 and 28) maintain control of disease until week 68 with prolonged treatment intervals of 16 weeks (guselkumab 100 mg every 16 weeks).","primaryOutcome":{"measure":"Group 2a and Group 2b: Percentage of Participants Who Achieved an Absolute Psoriasis Area and Severity Index (PASI) Score Less Than (<) 3 at Week 68","timeFrame":"Week 68","effectByArm":[{"arm":"Group 2a: Guselkumab 100 mg Q8W","deltaMin":92.6,"sd":null},{"arm":"Group 2b: Guselkumab 100 mg Q16W","deltaMin":91.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0013"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":90,"countries":["France","Germany"]},"refs":{"pmids":["39083288","34518264"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":38,"n":880},"commonTop":["Nasopharyngitis","Headache","Hypertension","Arthralgia","Back Pain"]}}